IMPROVED LUNG FUNCTION
UP TO 480 mL

BASELINE BLOOD EOS ≥300 CELLS/µL

Lung function improvement when added to SOC1

Change in lung function over
1 year (secondary endpoint)
BASELINE BLOOD EOS ≥300 CELLS/µL Trial 2

Significant improvements vs placebo at Week 12 (secondary endpoint) and at Week 52 (secondary endpoint) in patients with EOS ≥300 cells/µL

Week 12: 470 mL improvement from baseline in pre-bronchodilator FEV1 with DUPIXENT 300 mg + SOC (n=277) vs 220 mL with placebo + SOC (n=142) (LSM difference: 240 mL [95% Cl: 160, 320 mL])1

Week 52: 480 mL improvement from baseline in pre-bronchodilator FEV1 with DUPIXENT 300 mg + SOC (n=277) vs 230 mL with placebo + SOC (n=142)1

FEV1, forced expiratory volume in 1 second; LSM, least squares mean.

Rapid and sustained improvement in lung function through 52 weeks1-3,a

Change in lung function over 1 year (secondary endpoint)
NO BIOMARKER REQUIREMENT (ITT POPULATION) Trial 2

Significant improvements vs placebo at Week 12 (primary endpoint) and at Week 52 (secondary endpoint) in the ITT population

Week 12: 340 mL improvement from baseline in pre-bronchodilator FEV1 with DUPIXENT 300 mg + SOC (n=633) vs 210 mL with placebo + SOC (n=321) (LSM difference: 130 mL [95% Cl: 80, 180 mL])1,3

Week 52: 350 mL improvement from baseline in pre-bronchodilator FEV1 with DUPIXENT 300 mg + SOC vs 220 mL with placebo + SOC (LSM difference: 130 mL [95% CI: 80, 190 mL])3

In Trial 2, a significant difference from placebo + SOC was not observed at 12 weeks in change in pre-bronchodilator FEV1 in patients with baseline blood eosinophil levels ≥150 to <300 cells/μL taking DUPIXENT 300 mg + SOC and in patients with baseline blood eosinophil levels <150 cells/μL taking DUPIXENT 200 mg or 300 mg + SOC.1

  • a ITT population was unrestricted by minimum baseline eosinophils or other Type 2 biomarkers (eg, FeNO or IgE).2

See patient types with compromised lung function appropriate for DUPIXENT

VIEW PATIENTS

References:

  1. DUPIXENT Prescribing Information.
  2. Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486-2496.
  3. Data on file, Sanofi US. QUEST CSR efficacy response data, 2017.